Can You Advertise BPC-157, and What Does the FDA Categorisation Mean?

What the categorisation is

Compounding pharmacies may use bulk drug substances in defined circumstances, and the FDA maintains an evaluation process for substances nominated for that use. Substances are sorted into categories reflecting the agency's assessment, and several peptides that became commercially popular were placed in the category identifying significant safety risks. MedScale works only with telehealth brands, and this categorisation is usually the single most important fact about whether a given peptide has a viable marketing path.

The exact status of individual substances has continued to develop, so any specific determination should be confirmed against current FDA publications and with regulatory counsel rather than taken from a marketing article.

Why a compounding classification reaches marketing

It reaches marketing through two routes that operate independently of each other.

• Supply. A categorisation that discourages or precludes compounding affects whether the product can be lawfully supplied at all, which is upstream of every marketing question.
• Platform classification. Advertising policies prohibit promoting unapproved substances, and a public regulatory determination that a substance carries significant safety risk is exactly the kind of signal that places it there.

The second route is the one brands underestimate. A regulatory categorisation is public, durable and easy for a platform to reference, which makes it a poor thing to be on the wrong side of.

The gap between availability and advertisability

Peptides in this position often remain visibly available for purchase, which brands reasonably read as evidence that marketing them is viable. The two are not connected. Availability reflects enforcement capacity and market behaviour; advertisability reflects platform policy, which is enforced by automated review at scale.

The result is a category that looks commercially active while being largely unreachable through paid channels, which is a genuinely confusing position for a founder to be in.

What responsible marketing looks like here

For brands continuing to operate in this space, the defensible positions share common features: accurate description of regulatory status rather than silence about it, no therapeutic claims that the evidence base does not support, and no framing that implies approval which does not exist.

Research framing deserves particular caution. Describing a product as not for human consumption while operating a consumer purchase funnel creates a contradiction between the stated purpose and the actual one, and that contradiction is itself a misrepresentation problem.

Treating it as a portfolio question

The practical response for a multi-product telehealth brand is to know which parts of the catalogue can carry paid acquisition and which cannot, and to structure business assets so the constrained products cannot jeopardise the unconstrained ones.

MedScale approaches this as portfolio planning rather than campaign optimisation. Deciding which products paid acquisition can support is a more useful exercise than repeatedly testing creative for products no channel will accept.